Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 93 of 668 for:    CARBON DIOXIDE AND arterial

AZ, MZ, and the Pulmonary System Response to Hypoxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02760121
Recruitment Status : Completed
First Posted : May 3, 2016
Last Update Posted : October 19, 2016
Sponsor:
Information provided by (Responsible Party):
University of British Columbia

Brief Summary:
The purpose of this proposal is to compare the physiological effects of acetazolamide (AZ) and methazolamide (MZ) on the control of breathing and hypoxic pulmonary vasoconstriction. The first objective is to assess the effects of AZ and MZ on the control of breathing in normoxia and hypoxia. To achieve this the ventilatory interaction between oxygen and carbon dioxide will be measured and effects compared between placebo, AZ, and MZ conditions. In addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic ventilatory response will be measured with each drug. The second objective is to assess the effects of AZ and MZ on the control of the pulmonary vasculature during hypoxia. Pulmonary pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.

Condition or disease Intervention/treatment Phase
Altitude Sickness Hypertension, Pulmonary Drug: Acetazolamide Drug: Methazolamide Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia
Study Start Date : May 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Acetazolamide
Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
Drug: Acetazolamide
Experimental: Methazolamide
Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
Drug: Methazolamide
Placebo Comparator: Placebo
Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
Drug: Placebo



Primary Outcome Measures :
  1. Change in ventilation [ Time Frame: Baseline and 60 minutes of poikilocapnic hypoxia ]
    To quantify the isocapnic hypoxic ventilatory response, the hypercapnic ventilatory response, and the hypercapnic hypoxic ventilatory response, ventilation will be measured throughout controlled changes in end-tidal gas levels. Each protocol will consist of 90s steps in end-tidal oxygen partial pressure from baseline through 65, 57, and 47 mmHg. For hypercapnic hypoxia, the end-tidal partial pressure for carbon dioxide will be increased from baseline to +6 mmHg for 7 minutes before reducing the end-tidal partial pressure of oxygen as above. The poikilocapnic hypoxic ventilatory response will be determined by measuring the change in ventilation from baseline throughout 60 minutes of poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)

  2. Change in pulmonary artery pressure [ Time Frame: Baseline and 60 minutes of poikilocapnic hypoxia ]
    Pulmonary artery systolic pressure (PASP) will be derived using the modified Bernoulli equation and the regurgitant velocity across the tricuspid valve. Estimates of right atrial pressure will be evaluated based upon the collapsibility index of the inferior vena cave during a sniff test. The pulmonary artery pressure response will be measured during 60 minutes of exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)


Secondary Outcome Measures :
  1. Change in cerebral blood velocity [ Time Frame: Baseline and 60 minutes ]
    To quantify the isocapnic hypoxic cerebral blood velocity response, the hypercapnic cerebral blood velocity response, and the hypercapnic hypoxic cerebral blood velocity response, cerebral blood velocity in the middle and posterior cerebral arteries will be measured throughout controlled changes in end-tidal gas levels. Each protocol will consist of 90s steps in end-tidal oxygen partial pressure from baseline through 65, 57, and 47 mmHg. For hypercapnic hypoxia, the end-tidal carbon dioxide partial pressure will be increased from baseline to +6 mmHg for 7 minutes before reducing the end-tidal oxygen partial pressure as above. The poikilocapnic hypoxic ventilatory response will be determined by measuring the change in ventilation from baseline throughout 60 minutes of poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)


Other Outcome Measures:
  1. change in arterial oxygen partial pressure [ Time Frame: Baseline and 60 minutes ]
  2. Change in arterial carbon dioxide partial pressure [ Time Frame: Baseline and 60 minutes ]
  3. Change in arterial pH [ Time Frame: Baseline and 60 minutes ]
  4. Change in heart rate [ Time Frame: Baseline and 60 minutes ]
  5. change in blood pressure [ Time Frame: Baseline and 60 minutes ]
  6. change in end-tidal oxygen and carbon dioxide partial pressure [ Time Frame: Baseline and 60 minutes ]
  7. Change in arterial oxygen saturation [ Time Frame: Baseline and 60 minutes ]
  8. Change in cardiac output [ Time Frame: Baseline and 60 minutes of poikilocapnic hypoxia ]
    Cardiac output will be determined using the aortic time integral velocity and the diameter of the aortic valve annulus. Data will be collected at baseline and throughout exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)

  9. Change in pulmonary venous blood velocity [ Time Frame: Baseline and 60 minutes of poikilocapnic hypoxia ]
    Doppler ultrasound will be used to measure the velocity of blood draining from the pulmonary vein at baseline and throughout exposure to poikilocapnic hypoxia (fraction of inspired oxygen = 0.12)

  10. Hemoglobin [ Time Frame: Baseline ]
  11. albumin [ Time Frame: Baseline ]
  12. iron [ Time Frame: Baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-40 years of age
  • regularly physically active
  • male

Exclusion Criteria:

  • ex-smokers
  • pulmonary function <80% of predicted
  • contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)
  • Obese (BMI>30Kg/m2)
  • diuretic medication use
  • blood thinner use
  • anti-platelet drug use.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02760121


Locations
Layout table for location information
Canada, British Columbia
University of British Columbia
Kelowna, British Columbia, Canada, V1V 1V7
Sponsors and Collaborators
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Glen E Foster, Ph.D. University of British Columbia

Layout table for additonal information
Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT02760121     History of Changes
Other Study ID Numbers: H16-00028
First Posted: May 3, 2016    Key Record Dates
Last Update Posted: October 19, 2016
Last Verified: October 2016
Keywords provided by University of British Columbia:
Acetazolamide
Methazolamide
Control of breathing
Hypoxic pulmonary vasoconstriction
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Altitude Sickness
Hypoxia
Signs and Symptoms, Respiratory
Signs and Symptoms
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Acetazolamide
Methazolamide
Anticonvulsants
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs